Insmed Inc (INSM)

$136.00 -8.00 (-5.56%)
Market Cap 29.32B
Revenue (ttm) 606.42M
Net Income (ttm) -1.28B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -210.54%
Debt to Equity Ratio 0.73
Volume 4,561,500
Avg Vol 2,493,356
Day's Range N/A - N/A
Shares Out 215.55M
Stochastic %K 2%
Beta 1.13
Analysts Strong Sell
Price Target $213.80

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor o...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 977 9900
Address:
700 US Highway 202/206, Bridgewater, United States
Night_Owl_Biotech
Night_Owl_Biotech Mar. 22 at 1:23 AM
31% (28 of 90) commercial-stage bios are trading at 3.5 month lows (since 12/1/25). There are 90 such comm'l-stage bios (oncology with market caps north of $300MM & non over $800MM). We exclude "Big Pharma" stocks in this peer group. The attachment lists all 28 with their corresponding change in share price versus their 3.5 month high $ARGX ONC $INSM INCY & $GMAB are 5 that trade at the highest valuations in this peer group and are all trading at 3.5 month lows. The $XBI is more or less trading at its 3.5 month low (off 9% from its 3.5 month high). We believe $TVTX could be a very interesting opportunity should the FDA approve Filspari for FSGS (though some say the PDUFA will be extended again). This is not investment advice. That being said, some investors recommend buying when quality stocks are trading at lows.
0 · Reply
Dy2ski
Dy2ski Mar. 20 at 6:29 PM
$INSM Yeah, Options expiry day, low volume and all today but the 3 month chart here is undeniably FUGLY! We were spoiled last year... 😐
0 · Reply
pianoman439
pianoman439 Mar. 17 at 6:06 PM
$INSM I like the action this week!
1 · Reply
notreload_ai
notreload_ai Mar. 16 at 4:45 PM
$DSGN , $RVMD , $KYMR , $IMTX , $INSM ... Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228). https://notreload.xyz/jefferies-biotech-buys-dsgn-rvmd-kymr-more-in-2026/
0 · Reply
killbilltrader
killbilltrader Mar. 16 at 3:59 PM
$BCRX could be $INSM I guess
0 · Reply
bemore
bemore Mar. 16 at 2:49 PM
$INSM Darwin Global Management Ltd. raised its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,457,445 shares of the biopharmaceutical company's stock after acquiring an additional 1,112,824 shares during the period. Insmed makes up 80.5% of Darwin Global Management Ltd.'s portfolio, making the stock its largest holding. Darwin Global Management Ltd. owned approximately 9.59% of Insmed worth $2,897,797,000 as of its most recent filing with the SEC.
0 · Reply
bemore
bemore Mar. 16 at 2:02 PM
$INSM Jefferies assumed coverage of Insmed (INSM) with a Buy rating and a price target of $228, up from $219. Insmed is to the respiratory space like Vertex Pharmaceuticals (VRTX) is to cystic fibrosis , a “category-defining and category-winning biotech,” the analyst tells investors. Brinsupri “looks on track to be one of the best launches of the decade,” with early sales data, survey work, and a clean competitive setup supporting “a credible path” to over $8B peak sales in bronchiectasis, the analyst added.
2 · Reply
pianoman439
pianoman439 Mar. 12 at 2:34 PM
$INSM mucho gracias short sellers!
0 · Reply
pianoman439
pianoman439 Mar. 12 at 11:30 AM
$INSM I missed this one, but BofA upped Insmed pt to 211 after the earnings call.
0 · Reply
deepak1285
deepak1285 Mar. 11 at 8:52 PM
$INSM well that was some after hours fuckery
1 · Reply
Latest News on INSM
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 11:00 AM EDT - 11 days ago

Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 5, 2026, 7:00 AM EST - 16 days ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Baron Health Care Fund Q4 2025 Contributors And Detractors

Mar 3, 2026, 10:18 AM EST - 18 days ago

Baron Health Care Fund Q4 2025 Contributors And Detractors

ACLX ARGX DOCS EHC LLY RDNT SYK

Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 12:17 PM EST - 19 days ago

Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells

Feb 26, 2026, 7:30 AM EST - 23 days ago

Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells

ARGX BKR BLD COHR DUOL FROG IOT

Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript

Feb 19, 2026, 12:55 PM EST - 4 weeks ago

Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

Feb 19, 2026, 7:00 AM EST - 4 weeks ago

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

Insmed To Present at March 2026 Investor Conferences

Feb 13, 2026, 7:00 AM EST - 5 weeks ago

Insmed To Present at March 2026 Investor Conferences

Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

Feb 5, 2026, 7:00 AM EST - 6 weeks ago

Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch

Feb 2, 2026, 8:15 AM EST - 6 weeks ago

Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch

Artisan Global Opportunities Fund Q4 2025 Portfolio Update

Jan 29, 2026, 9:39 AM EST - 7 weeks ago

Artisan Global Opportunities Fund Q4 2025 Portfolio Update

ARGX BKR BSX COF COIN LEG LHX

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

Jan 28, 2026, 7:00 AM EST - 7 weeks ago

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

Artisan Small Cap Fund Q4 2025 Portfolio Activity

Jan 23, 2026, 9:08 AM EST - 2 months ago

Artisan Small Cap Fund Q4 2025 Portfolio Activity

BRKR CLBT FLEX GH HXL IRTC ITGR

Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity

Jan 19, 2026, 10:30 PM EST - 2 months ago

Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity

ALAB ARGX COHR CRM CVNA DASH FERG

Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:16 PM EST - 2 months ago

Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Insmed CEO Will Lewis talks its rare disease drug pipeline

Jan 12, 2026, 6:14 PM EST - 2 months ago

Insmed CEO Will Lewis talks its rare disease drug pipeline

Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances

Jan 9, 2026, 10:58 AM EST - 2 months ago

Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 2 months ago

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 7:00 AM EST - 2 months ago

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

Dec 29, 2025, 9:29 PM EST - 2 months ago

INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news

Dec 18, 2025, 6:09 PM EST - 3 months ago

Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news

Why Is Insmed Stock Falling Thursday?

Dec 18, 2025, 12:30 PM EST - 3 months ago

Why Is Insmed Stock Falling Thursday?

Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dec 18, 2025, 8:04 AM EST - 3 months ago

Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BIRK

Insmed Stock Plummets 19%. This Is What Sparked the Selloff.

Dec 18, 2025, 7:12 AM EST - 3 months ago

Insmed Stock Plummets 19%. This Is What Sparked the Selloff.

Top 3 Health Care Stocks You'll Regret Missing This Quarter

Dec 18, 2025, 7:00 AM EST - 3 months ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

LEGN TEM

Insmed scraps development of sinus drug after mid-stage study failure

Dec 17, 2025, 5:35 PM EST - 3 months ago

Insmed scraps development of sinus drug after mid-stage study failure

Insmed Provides Clinical and Business Update

Dec 17, 2025, 4:01 PM EST - 3 months ago

Insmed Provides Clinical and Business Update

Eight stock picks to play one of the healthiest corners of the market

Dec 11, 2025, 10:37 AM EST - 3 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND MASI NTRA PODD UNH WGS

Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 12:53 PM EST - 3 months ago

Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript

These 15 stocks are still showing momentum — and a market-beating edge

Nov 20, 2025, 3:45 PM EST - 4 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH LITE MP MU

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Nov 18, 2025, 11:00 AM EST - 4 months ago

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 5:48 AM EST - 4 months ago

Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Nov 13, 2025, 7:00 AM EST - 4 months ago

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

Nov 6, 2025, 8:10 AM EST - 4 months ago

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

AMZN BSX DKS LHX SPOT TEAM VRTX

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

Nov 5, 2025, 8:10 AM EST - 4 months ago

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

AAPL ALNY APP CMG GOOGL NFLX STZ

Insmed To Present at November and December 2025 Investor Conferences

Nov 5, 2025, 7:00 AM EST - 4 months ago

Insmed To Present at November and December 2025 Investor Conferences

Latest read on rare disease gene therapy from Insmed CEO Will Lewis

Nov 3, 2025, 6:13 PM EST - 4 months ago

Latest read on rare disease gene therapy from Insmed CEO Will Lewis

Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:16 AM EDT - 5 months ago

Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 7:00 AM EDT - 5 months ago

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

Oct 27, 2025, 1:27 PM EDT - 5 months ago

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

ARGX BSX ISRG LLY RDNT

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

Oct 23, 2025, 4:05 PM EDT - 5 months ago

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Oct 17, 2025, 7:00 AM EDT - 5 months ago

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Oct 16, 2025, 7:00 AM EDT - 5 months ago

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Oct 15, 2025, 7:00 AM EDT - 5 months ago

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality

Sep 30, 2025, 2:33 PM EDT - 6 months ago

Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Sep 22, 2025, 7:00 AM EDT - 6 months ago

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:10 PM EDT - 6 months ago

Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 10:49 AM EDT - 7 months ago

Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Insmed To Present at September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 7 months ago

Insmed To Present at September Investor Conferences

Night_Owl_Biotech
Night_Owl_Biotech Mar. 22 at 1:23 AM
31% (28 of 90) commercial-stage bios are trading at 3.5 month lows (since 12/1/25). There are 90 such comm'l-stage bios (oncology with market caps north of $300MM & non over $800MM). We exclude "Big Pharma" stocks in this peer group. The attachment lists all 28 with their corresponding change in share price versus their 3.5 month high $ARGX ONC $INSM INCY & $GMAB are 5 that trade at the highest valuations in this peer group and are all trading at 3.5 month lows. The $XBI is more or less trading at its 3.5 month low (off 9% from its 3.5 month high). We believe $TVTX could be a very interesting opportunity should the FDA approve Filspari for FSGS (though some say the PDUFA will be extended again). This is not investment advice. That being said, some investors recommend buying when quality stocks are trading at lows.
0 · Reply
Dy2ski
Dy2ski Mar. 20 at 6:29 PM
$INSM Yeah, Options expiry day, low volume and all today but the 3 month chart here is undeniably FUGLY! We were spoiled last year... 😐
0 · Reply
pianoman439
pianoman439 Mar. 17 at 6:06 PM
$INSM I like the action this week!
1 · Reply
notreload_ai
notreload_ai Mar. 16 at 4:45 PM
$DSGN , $RVMD , $KYMR , $IMTX , $INSM ... Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228). https://notreload.xyz/jefferies-biotech-buys-dsgn-rvmd-kymr-more-in-2026/
0 · Reply
killbilltrader
killbilltrader Mar. 16 at 3:59 PM
$BCRX could be $INSM I guess
0 · Reply
bemore
bemore Mar. 16 at 2:49 PM
$INSM Darwin Global Management Ltd. raised its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,457,445 shares of the biopharmaceutical company's stock after acquiring an additional 1,112,824 shares during the period. Insmed makes up 80.5% of Darwin Global Management Ltd.'s portfolio, making the stock its largest holding. Darwin Global Management Ltd. owned approximately 9.59% of Insmed worth $2,897,797,000 as of its most recent filing with the SEC.
0 · Reply
bemore
bemore Mar. 16 at 2:02 PM
$INSM Jefferies assumed coverage of Insmed (INSM) with a Buy rating and a price target of $228, up from $219. Insmed is to the respiratory space like Vertex Pharmaceuticals (VRTX) is to cystic fibrosis , a “category-defining and category-winning biotech,” the analyst tells investors. Brinsupri “looks on track to be one of the best launches of the decade,” with early sales data, survey work, and a clean competitive setup supporting “a credible path” to over $8B peak sales in bronchiectasis, the analyst added.
2 · Reply
pianoman439
pianoman439 Mar. 12 at 2:34 PM
$INSM mucho gracias short sellers!
0 · Reply
pianoman439
pianoman439 Mar. 12 at 11:30 AM
$INSM I missed this one, but BofA upped Insmed pt to 211 after the earnings call.
0 · Reply
deepak1285
deepak1285 Mar. 11 at 8:52 PM
$INSM well that was some after hours fuckery
1 · Reply
kelrock90
kelrock90 Mar. 11 at 8:30 PM
$INSM After hours $128.43 is sketchy. Anyone want to give words of wisdom here. Sick and tired of the bleeding for no good reason
1 · Reply
bemore
bemore Mar. 10 at 6:27 PM
$INSM post from Bo at IV board, I thought that Sara Bonstein did a good job. Since we all follow Insmed, we are usually aware of what is spoken about at these conferences. One thing she said that I had not heard before, was what she said about the COPD and Asthma patients that currently may be co morbid with Bronchiectasis. I was aware that COPD patients that also have bronchiectasis was somewhere between 4 and 50%. Sara said that the most recent literature is now putting that number between 30 and 50%. There are 20 million COPD patients in the U.S. I wrote down what she said about the market for Brinsupri, because it was kind of stunning. I think it's OK if I use quotations because I kept going back and tried to write it word for word. "The company has guided to max sales of 5 billion, but that is just for diagnosed patients today, and does not include all of the low hanging fruit that could be multiples of that."
0 · Reply
bemore
bemore Mar. 10 at 6:26 PM
$INSM Regarding TPIP, she said that when Flammer called her with the results she was shocked, and had to have it repeated three times. She said "I just couldn't believe what my ears were hearing." A 35% reduction in pulmonary vascular resistance along with a 35 meter increase in the six minute walk was just to hard for her to believe.
0 · Reply
pianoman439
pianoman439 Mar. 10 at 3:42 PM
$INSM Sara was lit 🔥 at Leerink!
1 · Reply
Zinsinus
Zinsinus Mar. 7 at 5:28 PM
$INSM 85 jobs filled with inducement grant press release. Still a ton of jobs open on their website
0 · Reply
OptionRunners
OptionRunners Mar. 5 at 7:28 PM
Took the L on $INSM calls. Breaking down through daily support here. $4.10 to $2.60 on them.
0 · Reply
pianoman439
pianoman439 Mar. 5 at 7:27 PM
$INSM thanks for more cheap shares!
2 · Reply
Quantumup
Quantumup Mar. 5 at 6:17 PM
Raymond James reiterated $LQDA at a Strong Buy rating and a $47 PT. $UTHR $INSM JNJ MRK Here's what Raymond James had to say in its note to investors: https://x.com/Quantumup1/status/2029621616997716079?s=20
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Mar. 5 at 12:14 PM
$INSM @Doozio chop chop huckleberries? 👀
1 · Reply
OptionRunners
OptionRunners Mar. 4 at 7:42 PM
$INSM I joined
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 11:59 PM
$INSM Current Stock Price: $146.95 Contracts to trade: $145.0 INSM Mar 20 2026 Call Entry: $6.70 Exit: $11.86 ROI: 77% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply